Scancell Holdings Plc · LSE:SCLP
Scancell — Shareholder Meeting (November 2023)
26 slides from Scancell's shareholder meeting presentation, November 2023
Slide 1: Developing Antibodies and Vaccines for Cancer
DEVELOPING ANTIBODIES AND VACCINES FOR CANCER Highly impressive clinical data for lead asset SCIB1 that could make a significant impact on melanoma patient survival Lindy Durrant, CEO Sath Nirmalananthan, CFO Jean-Michel Cosséry, Non-Executive Chairman November 2023 LSE: SCLP.L
Slide 2: Scancell at a glance
Scancell at a glance USP: Novel targets in immuno-oncology A world-leader in cancer Specialist investor backing Experienced team focused vaccines and antibodies and strong financial on delivery position • Clinical stage company with two • AIM listed and backed by blue • Experienced board, leadership
Slide 3: Skilled Leadership team
Skilled Leadership team Lindy Durrant, CEO & CSO Sath Nirmalananthan, CFO Sally Adams, CDO Dr Mandeep Sehmi, Head of Robert Miller, Medical Director Internationally recognised Experienced finance professional Engaged in several senior Business Development Trained as a cardiothoracic surgeon immunolo
Slide 4: Growing innovative Pipeline
Growing innovative Pipeline Near term focus on clinical development of SCIB1/iSCIB1+ & Modi-1 Product Indication Research Preclinical Phase 1 Phase 2 Phase 3 SCIB1/ Late-stage iSCIB1+ melanoma (SCOPE study) Vaccines TNBC, ovarian, Modi-1 renal, head & (ModiFy study) neck Multiple, solid Modi-2 tumou
Slide 5: Scancell development highlights
Scancell development highlights Clinically validated vaccine and antibody technology platforms with multiple value drivers Non-personalised cancer vaccines Vaccine platform 1 (SCIB1 from Immunobody®): ► Impressive Phase 2 early efficacy data on the first 11 patients treated with SCIB1/CPIs in melano
Slide 6: SCIB1 for unresected metastatic melanoma
SCIB1 for unresected metastatic melanoma Stimulating potent killer T cells November 23 6
Slide 7: SCIB1 is a competitive vaccine in the Oncology Vaccine Space
SCIB1 is a competitive vaccine in the Oncology Vaccine Space ► Personalised mRNA vaccines (e.g., Moderna, BioNTech) pose economic and technical challenges ► Not off the shelf, several weeks to prepare, need a biopsy, adding to cost to make and distribute ► Uses multiple unvalidated epitopes which li
Slide 8: Clinical development landscape – unresectable melanoma
Clinical development landscape – unresectable melanoma Resectable melanoma Unresectable Stage III/IV melanoma Moderna and Merck Stage III/IV neoantigen vaccine ► Scancell are in unresected melanoma treated with double checkpoint anti-PD1 2nd Line and anti-CTLA-4. Potential $1.5bn1 market 1st Line (S
Slide 9: SCOPE trial of SCIB1 our lead asset
SCOPE trial of SCIB1 our lead asset Patient population Histologically confirmed, unresectable AJCC stage III or stage IV melanoma No prior systemic treatment for advanced disease Suitable for treatment with ipilimumab and nivolumab, with measurable disease Simon stage 1 >8/15 ORR; Simon stag
Slide 10: Strong early clinical results from stage one of SCOPE study
Strong early clinical results from stage one of SCOPE study- September SCIB1 in combination with CPIs PD = progressive disease; PR = partial response From the 11 first patients recruited and analysed so far: Why should we get excited about… 11 patients? ► 9/11 patients have shown a response ► Recrui
Slide 11: SCOPE update – November 2023
SCOPE update – November 2023 September 2023 November 2023 ► 9/11 patients responded ► 11/13 patients responded ► One stable (patient #2) ► 9 confirmed partial responses at 19+ weeks ► One patient progressed (patient #1) ► 1 CR November 23 11
Slide 12: SCIB1 is now ready to pursue the unresected melanoma market
SCIB1 is now ready to pursue the unresected melanoma market Potential to help patients not covered by current treatments ► SCIB1 is being developed in cutaneous melanoma –compelling efficacy data ► Post resection patients: 95% disease-free survival (DFS) at 12 months and 88% at 5 years ► Unresected
Slide 13: Vaccines 2. Moditope®
Vaccines 2. Moditope® Stimulating pro-inflammatory killer CD4 T cells November 23 13
Slide 14: Modi-1 with a unique mechanism of action
Modi-1 with a unique mechanism of action Moditope® platform stimulates pro-inflammatory killer CD4 T cells to post-translational modifications ► Composed of combination of three citrullinated peptides linked to an adjuvant, from two target antigens that are commonly modified in cancer cells ► Viment
Slide 15: ModiFY Phase 1/2 trial of Modi-1 actively recruiting patients
ModiFY Phase 1/2 trial of Modi-1 actively recruiting patients in four different tumour indications November 23 15
Slide 16: ModiFY: First complete cohort of Modi-1 monotherapy in advanced Ovarian cancer
ModiFY: First complete cohort of Modi-1 monotherapy in advanced Ovarian cancer ► 16 patients scanned and 7 stable responses by RECIST (44%). Stable disease = between 20% and -30% change in target lesion size with no new lesions present ► Data similar to monotherapy SCIB1 in unresected patients ► Sho
Slide 17: ModiFY trial now recruiting for monotherapy and combination with CPIs
ModiFY trial now recruiting patients for monotherapy and for Modi-1 in combination with CPIs 44% of actively progressing ovarian cancer patients achieved stable disease ► Ovarian monotherapy cohort fully recruited (n=16) ► All patients failed on previous treatments and with actively progressing dise
Slide 18: Antibodies: Targeting glycans preferentially expressed on tumours
ANTIBODIES Targeting glycans preferentially expressed on tumours November 23 18
Slide 19: GlyMab® – unlocking the value of tumour glycans
GlyMab® – unlocking the value of tumour glycans ► Scancell has the know how to make high affinity, humanised/human IgG anti-glycan antibodies ► Portfolio of patent protected anti-glycan antibodies with excellent specificity, binding strongly to tumours and showing restricted normal tissue expression
Slide 20: AvidiMab® – a proprietary platform for enhancing the avidity of antibodies
AvidiMab® – a proprietary platform for enhancing the avidity of antibodies AvidiMab® modification of SC129 What is it? A proprietary platform for enhancing the reduces the off-rate avidity of antibodies What does it do? Promotes non-covalent Fc-Fc interactions of antibodies Why is it important? It c
Slide 21: Anti-Glycan antibodies uniquely positioned in a booming market
Anti-Glycan antibodies uniquely positioned in a booming market Anti-glycan antibodies have exquisite tumour specificity and can be developed into multiple products ► Scancell is one of only a few companies worldwide with the know how to make high affinity anti-glycan monoclonal antibodies (mAbs) ► P
Slide 22: Financials, Timelines and Outlook
Financials, Timelines and Outlook November 23 22
Slide 23: Scancell Key Financial Highlights
Scancell Key Financial Highlights £’m 2023 2022 • Revenue of £5.3m reflects the first milestone Restated payment from Genmab licensing deal. Revenue 5.3m - Development on track to meet future clinical and regulatory milestones Development Expenses (11.6m) (9.5m) Administrative Expenses (5.0m) (4.8m)
Slide 24: Strong pipeline of news flow over next years
Strong pipeline of news flow over next 2 years 2023 H1 2024 H2 2024 2025 SCIB1 +CPI SCIB1/ 27/43 (34) responses SCIB1 + CPI Phase 2/3 registration Results of iSCIB1+ Vaccines 9/11 responses study1 Phase 2 randomised trial SCOPE iSCIB1+ 9/11 responses Modi-1 Modi-1/CPI & neoadjuvant Early clinical re
Slide 25: Outlook
Outlook Near term clinical milestones and value drivers SCOPE Study • Second stage recruitment of SCOPE study with SCIB1 of 43 patients • Second stage SCOPE efficacy data with SCIB1 available in H1 2024 • Phase 2/3 seamless adaptive registration trial with SCIB1 or iSCIB1+ to begin in 2024 ModiFY •
Slide 26: Thank you
Thank you www.scancell.co.uk November 23 26
Scancell Holdings — Shareholder Meeting (November 2023) on 6ix